Irwin Naturals Inc. (CSE:IWIN) has reported its financial results for the fourth quarter and year ended December 31, 2022, a period in which it commenced its expansion into the high-growth cannabis and psychedelics sectors.
In the results statement, Klee Irwin, the company's CEO, commented: “In Q4, we continued to invest in our Emergence clinics and cannabis business lines. Our investment in Emergence now includes eight acquisitions, consisting of 13 clinics, and one advertising platform.
"We are currently moving forward with phase two of our plan to become the world’s largest chain of dedicated psychedelic mental health clinics through organic growth and development and are currently reviewing options for the first Emergence branded clinic in the United States.
"Additionally, we anticipate seeing considerable growth coming from our Cannabis business line with the first revenues from our licensing deals to occur in Q2 2023, which now sees us in seven states and in Canada.”
The company reported annual revenue of $89.5 million, a 10.8% decrease from the previous year's $100.3 million, primarily due to a decrease in business volume.
Income from operations decreased from $10.6 million in 2021 to $1.8 million in 2022, reflecting the impact of reduced business volume and startup costs related to the company's acquisitions in 2022, specifically Irwin Naturals Emergence, which acquired 12 mental health clinics, and Irwin Naturals Cannabis, involved in intellectual property licensing to the cannabis industry.
Irwin Naturals achieved significant operational milestones in the fourth quarter of 2022 and the year-to-date period of 2023. The company completed the acquisition of Care Clinic Inc, known as Florida Mind Health Center, and secured a credit facility with its existing commercial lender for $40 million, potentially reaching $60 million.
Furthermore, Irwin Naturals announced licensing agreements with renowned cannabis product developers in Oregon and a partner in Oklahoma to manufacture and distribute THC cannabis products.
Commenting on the company's expansion efforts, Sean Sand, CFO of Irwin Naturals, said: "We have made the necessary investments in our operations to support sustained long-term growth by entering into several new licensing agreements to distribute Irwin Naturals branded cannabis products and expanded our mental health clinics footprint in Florida through an acquisition.”
Irwin Naturals also announced the appointment of Sheri Orlowitz as a new director, filling a vacancy left by a recent resignation from the board.
Irwin Naturals, renowned for its nutraceutical products, is aiming to offer THC-based products and establish itself as a leading provider of mental health clinics through its Emergence brand.
With a strong presence in North America, the company seeks to leverage its brand reputation to drive growth and expand its portfolio of plant-based healing solutions.
Contact the author at jon.hopkins@proactiveinvestors.com